Back

Twenty-year trends in peripheral artery disease, lower extremity revascularization, and lower extremity amputation in newly diagnosed type 2 diabetes

2 September 2024 (14:00 - 14:40)
Organised by: Logo
Congress Presentation Part of: Diseases of the aorta: new findings Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Christine Gyldenkerne

Aarhus University Hospital, Aarhus (Denmark)

5 More presentations in this session

Presentation thumbnail
Drug-coated balloon versus drug-eluting stent for femoropopliteal total occlusions: Intraluminal versus subintimal approaches
Slides Video
Presentation thumbnail
Comparative effectiveness of endovascular reconstruction techniques for the left subclavian artery in managing acute type B aortic dissection with an inadequate proximal landing zone
Slides Video
Presentation thumbnail
Developing a multi-center registry of peripheral artery disease using natural language processing: unlocking the power of the electronic health record
Associate Professor S. Girotra (Dallas, US)
Abstract Slides Video
Presentation thumbnail
Three-dimensional transthoracic vs transesophageal echocardiography vs computed tomography angiography aorta for aortic annular diameter measurement for TAVI in our hospital
Doctor S. Kieattisaksopon (Bangkok, TH)
Abstract Slides Video
Presentation thumbnail
Impact of comorbid coronary artery disease on short and medium-term outcomes after carotid artery stenting.
Doctor B. Resende (Coimbra, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Diseases of the aorta: new findings

The Event

Event poster

ESC Congress 2024

2 September 2024 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Intensity of glycemic control and risk of cardiovascular and limb events in peripheral artery disease
thumbnail
Congress Session
Cardiovascular and limb outcomes in peripheral artery disease
thumbnail
Congress Presentation
Biochemical profiles and risk of cardiovascular events in patients withType 2 Diabetes: implications for choice of novel antihyperglycemic therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources